By Royal Charter

EC Design-Examination Certificate

Directive 93/42/EEC on Medical Devices, Annex II Section 4

No. **CE 632827**

Issued To: **Abbott Vascular**
3200 Lakeside Drive
Santa Clara
California
95054
USA

In respect of:

XIENCE PRO Everolimus-eluting Coronary Stent Systems

BSI has performed a design examination on the above devices in accordance with the Council Directive 93/42/EEC, Annex II Section 4. The design conforms to the requirements of this directive. For marketing of these products an additional Annex II excluding Section 4 certificate is required.

For and on behalf of BSI, a Notified Body for the above Directive (Notified Body Number 2797):

Gary E Slack, Senior Vice President Medical Devices

First Issued: **2015-04-13** Date: **2021-03-18** Expiry Date: **2024-05-26**

...making excellence a habit.™

EC Design-Examination Certificate

Supplementary Information to CE 632827

Issued To:

Abbott Vascular
3200 Lakeside Drive
Santa Clara
California
95054
USA

Device Name: XIENCE PRO 48 Everolimus Eluting Coronary Stent System

Intended purpose per IFU:

Indications:
The XIENCE PRO 48 Everolimus Eluting Coronary Stent System is indicated for improving coronary luminal diameter in the following:

- Patients with symptomatic ischemic heart disease due to discrete *de novo* native coronary artery lesions.
- For restoring coronary flow in patients experiencing acute myocardial infarction who present within 12 hours of symptom onset.
- For the treatment of patients with concomitant diabetes, acute coronary syndrome, dual vessel lesions (two lesions in two different epicardial vessels), lesions residing within small coronary vessels; lesions where treatment results in the jailing of side branches (lesions with a side branch < 2 mm in diameter or an ostial stenosis < 50%); for the treatment of elderly patients (age ≥ 65), and for treatment of both men and women.
- For treatment of patients with high bleeding risk (HBR) under dual anti-platelet therapy (DAPT) as short as 28 days.
- For the treatment of patients presenting with in-stent restenosis in coronary artery lesions; chronic total occluded coronary artery lesions (defined as coronary artery lesions with TIMI flow 0 and lasting longer than 3 months); and coronary artery bifurcation lesions.

In all cases, the treated lesion length should be less than the nominal stent length (48 mm) with a reference vessel diameter of ≥ 2.50 mm and ≤ 3.75 mm.

Classification: Class III Implant

Catalog Numbers:

Stent Diameter [mm]	**Stent Length [mm]**
	48
2.50	1017250-48
2.75	1017275-48
3.00	1017300-48
3.50	1017350-48

First Issued: **2015-04-13** Date: **2021-03-18** Expiry Date: **2024-05-26**

...making excellence a habit.™

By Royal Charter

EC Design-Examination Certificate

Supplementary Information to CE 632827

Issued To:

Abbott Vascular
3200 Lakeside Drive
Santa Clara
California
95054
USA

Device Name: XIENCE PRO^{X} Everolimus Eluting Coronary Stent System

Intended purpose per IFU:

Indications:
The XIENCE PRO^{X} Everolimus Eluting Coronary Stent System is indicated for improving coronary luminal diameter in the following:

- Patients with symptomatic ischemic heart disease due to discrete *de novo* native coronary artery lesions
- For restoring coronary flow in patients experiencing acute myocardial infarction who present within 12 hours of symptom onset
- For the treatment of patients with concomitant diabetes, acute coronary syndrome, dual vessel lesions (two lesions in two different epicardial vessels), lesions residing within small coronary vessels; lesions where treatment results in the jailing of side branches (lesions with a side branch < 2 mm in diameter or an ostial stenosis < 50%); for the treatment of elderly patients (age ≥ 65), and for treatment of both men and women.
- For the treatment of patients presenting with in-stent restenosis in coronary artery lesions; chronic total occluded coronary artery lesions (defined as coronary artery lesions with TIMI flow 0 and lasting longer than 3 months); and coronary artery bifurcation lesions.

In all cases, the treated lesion length should be less than the nominal stent length (8 mm, 12 mm, 15 mm, 18 mm, 23 mm, 28 mm, 33mm or 38mm) with a reference vessel diameter of ≥ 2.00 mm and ≤ 4.25 mm.

Classification: Class III Implant

Catalog Numbers:

Stent Diameter [mm]	Stent Length [mm]							
	8	**12**	**15**	**18**	**23**	**28**	**33**	**38**
2.00	1076200-08	1076200-12	1076200-15	1076200-18	1076200-23	1076200-28	--	--
2.25	1076225-08	1076225-12	1076225-15	1076225-18	1076225-23	1076225-28	--	--
2.50	1076250-08	1076250-12	1076250-15	1076250-18	1076250-23	1076250-28	1076250-33	1076250-38
2.75	1076275-08	1076275-12	1076275-15	1076275-18	1076275-23	1076275-28	1076275-33	1076275-38
3.00	1076300-08	1076300-12	1076300-15	1076300-18	1076300-23	1076300-28	1076300-33	1076300-38
3.25	1076325-08	1076325-12	1076325-15	1076325-18	1076325-23	1076325-28	1076325-33	1076325-38
3.50	1076350-08	1076350-12	1076350-15	1076350-18	1076350-23	1076350-28	1076350-33	1076350-38
4.00	1076400-08	1076400-12	1076400-15	1076400-18	1076400-23	1076400-28	1076400-33	1076400-38

First Issued: **2015-04-13** Date: **2021-03-18** Expiry Date: **2024-05-26**

...making excellence a habit.™

EC Design-Examination Certificate

Supplementary Information to CE 632827

Issued To:

Abbott Vascular
3200 Lakeside Drive
Santa Clara
California
95054
USA

Device Name: XIENCE PRO[A] Everolimus Eluting Coronary Stent System

Intended purpose per IFU:

Indications:
The XIENCE PRO[A] Everolimus Eluting Coronary Stent System is indicated for improving coronary luminal diameter in the following:

- Patients with symptomatic ischemic heart disease due to discrete *de novo* native coronary artery lesions.
- For restoring coronary flow in patients experiencing acute myocardial infarction who present within 12 hours of symptom onset.
- For the treatment of patients with concomitant diabetes, acute coronary syndrome, dual vessel lesions (two lesions in two different epicardial vessels), lesions residing within small coronary vessels; lesions where treatment results in the jailing of side branches (lesions with a side branch < 2 mm in diameter or an ostial stenosis < 50%); for the treatment of elderly patients (age ≥ 65), and for treatment of both men and women.
- For treatment of patients with high bleeding risk (HBR) under dual anti-platelet therapy (DAPT) as short as 28 days.
- For the treatment of patients presenting with in-stent restenosis in coronary artery lesions; chronic total occluded coronary artery lesions (defined as coronary artery lesions with TIMI flow 0 and lasting longer than 3 months); and coronary artery bifurcation lesions.

In all cases, the treated lesion length should be less than the nominal stent length (8 mm, 12 mm, 15 mm, 18 mm, 23 mm, 28 mm, 33mm or 38mm) with a reference vessel diameter of ≥ 2.00 mm and ≤ 4.25 mm.

Classification: Class III Implant

Catalog Numbers:

Stent Diameter [mm]	Stent Length [mm]							
	8	**12**	**15**	**18**	**23**	**28**	**33**	**38**
2.00	1128200-08	1128200-12	1128200-15	1128200-18	1128200-23	1128200-28	--	--
2.25	1128225-08	1128225-12	1128225-15	1128225-18	1128225-23	1128225-28	--	--
2.50	1128250-08	1128250-12	1128250-15	1128250-18	1128250-23	1128250-28	1128250-33	1128250-38
2.75	1128275-08	1128275-12	1128275-15	1128275-18	1128275-23	1128275-28	1128275-33	1128275-38
3.00	1128300-08	1128300-12	1128300-15	1128300-18	1128300-23	1128300-28	1128300-33	1128300-38
3.25	1128325-08	1128325-12	1128325-15	1128325-18	1128325-23	1128325-28	1128325-33	1128325-38
3.50	1128350-08	1128350-12	1128350-15	1128350-18	1128350-23	1128350-28	1128350-33	1128350-38
4.00	1128400-08	1128400-12	1128400-15	1128400-18	1128400-23	1128400-28	1128400-33	1128400-38

First Issued: **2015-04-13** Date: **2021-03-18** Expiry Date: **2024-05-26**

...making excellence a habit.™

EC Design-Examination Certificate

Supplementary Information to CE 632827

Issued To:

Abbott Vascular
3200 Lakeside Drive
Santa Clara
California
95054
USA

Device Name: XIENCE PRO^{S} Everolimus Eluting Coronary Stent System

Intended purpose per IFU:

Indications:
The XIENCE PRO^{S} Everolimus Eluting Coronary Stent System is indicated for improving coronary luminal diameter in the following:

- Patients with symptomatic ischemic heart disease due to discrete de novo native coronary artery lesions.
- For restoring coronary flow in patients experiencing acute myocardial infarction who present within 12 hours of symptom onset.
- For the treatment of patients with concomitant diabetes, acute coronary syndrome, dual vessel lesions (two lesions in two different epicardial vessels), lesions residing within small coronary vessels; lesions where treatment results in the jailing of side branches (lesions with a side branch < 2 mm in diameter or an ostial stenosis < 50%); for the treatment of elderly patients (age ≥ 65), and for treatment of both men and women.
- For treatment of patients with high bleeding risk (HBR) under dual anti-platelet therapy (DAPT) as short as 28 days.
- For the treatment of patients presenting with in-stent restenosis in coronary artery lesions; chronic total occluded coronary artery lesions (defined as coronary artery lesions with TIMI flow 0 and lasting longer than 3 months); and coronary artery bifurcation lesions.

In all cases, the treated lesion length should be less than the nominal stent length (8 mm, 12 mm, 15 mm, 18 mm, 23 mm, 28 mm, 33 mm, or 38 mm) with a reference vessel diameter of ≥ 2.00 mm and ≤ 4.25 mm.

Classification: Class III Implant

Catalog Numbers:

Stent Diameter [mm]	Stent Length [mm]							
	8	**12**	**15**	**18**	**23**	**28**	**33**	**38**
2.00	1508200-08	1508200-12	1508200-15	1508200-18	1508200-23	1508200-28	1508200-33	1508200-38
2.25	1508225-08	1508225-12	1508225-15	1508225-18	1508225-23	1508225-28	1508225-33	1508225-38
2.50	1508250-08	1508250-12	1508250-15	1508250-18	1508250-23	1508250-28	1508250-33	1508250-38
2.75	1508275-08	1508275-12	1508275-15	1508275-18	1508275-23	1508275-28	1508275-33	1508275-38
3.00	1508300-08	1508300-12	1508300-15	1508300-18	1508300-23	1508300-28	1508300-33	1508300-38
3.25	1508325-08	1508325-12	1508325-15	1508325-18	1508325-23	1508325-28	1508325-33	1508325-38
3.50	1508350-08	1508350-12	1508350-15	1508350-18	1508350-23	1508350-28	1508350-33	1508350-38
4.00	1508400-08	1508400-12	1508400-15	1508400-18	1508400-23	1508400-28	1508400-33	1508400-38

First Issued: **2015-04-13** Date: **2021-03-18** Expiry Date: **2024-05-26**

...making excellence a habit.™

By Royal Charter

EC Design-Examination Certificate

Supplementary Information to CE 632827

Issued To:

Abbott Vascular
3200 Lakeside Drive
Santa Clara
California
95054
USA

Certificate History

Date	Reference Number	Action
13 April 2015	10154362	New Issue. Transfer from another Notified Body.
12 January 2016	10159718	DuPont Tyvek Medical Transition Project update.
24 November 2016	10166114	Certificate Renewal.
10 August 2017	8695169	Various IFU updates including revised risk and clinical use information and alignment of structure and general consistency. Update symbols on labels for consistency across project families.
22 December 2017	8868966	Add Synergy Health in Offaly, Ireland as new ETO sterilization site.
05 March 2018	8888512	Addition of product XIENCE PRO[A] as re-branding of the XIENCE Alpine with no design changes.
27 February 2019	7780598	Traceable to NB 0086.
14 October 2019	9749795	Addition of a new drug manufacturing site including minor adaptions to manufacturing process and update to testing monograph.
20 November 2019	3092491	Change of UPLC column used in the analytical testing for lot release.

First Issued: **2015-04-13** Date: **2021-03-18** Expiry Date: **2024-05-26**

...making excellence a habit.™

By Royal Charter

EC Design-Examination Certificate

Supplementary Information to CE 632827

Issued To:

Abbott Vascular
3200 Lakeside Drive
Santa Clara
California
95054
USA

Certificate History

Date	Reference Number	Action
12 January 2021	3079678	Certificate Renewal. Removal of product codes: - 1017225-08/-12/-15/-18/-23/-28 - 1017250-08/-12/-15/-18/-23/-28/-33/-38 - 1017275-08/-12/-15/-18/-23/-28/-33/-38 - 1017300-08/-12/-15/-18/-23/-28/-33/-38 - 1017350-08/-12/-15/-18/-23/-28/-33/-38 - 1017400-08/-12/-15/-18/-23/-28/-33/-38 Addition of product XIENCE PRO^S as re-branding of the XIENCE Sierra with no design changes. Update of the supplementary information page to include intended purpose per IFU and device classification as per current BSI template. Reformatting of device models tables. Words "and peripheral" removed from certificate scope.
Current	3329302	Update to IFU dual antiplatelet therapy recommendations for high bleeding risk patients and inclusion in the certificate intended purpose per IFU.

First Issued: **2015-04-13** Date: **2021-03-18** Expiry Date: **2024-05-26**

...making excellence a habit.™

By Royal Charter

EC Certificate - Full Quality Assurance System

Directive 93/42/EEC on Medical Devices, Annex II excluding Section 4

No. **CE 510108**

Issued To: **Abbott Vascular**
3200 Lakeside Drive
Santa Clara
California
95054
USA

In respect of:

The Design, Development and Manufacture of Sterile Coronary and Peripheral Dilatation Catheters, Stent Systems including Covered Stents, Drug Eluting Stents, Coronary Stents, Carotid Stents, and Peripheral Stents, Embolic Protection Systems, Femoral Vessel Closure Systems, Guidewires, Mitral and Tricuspid Valve Repair Systems, Inflation Devices, and Inflation Accessories.
Those aspects of Annex II related to securing and maintaining the sterility of Guide Wire Extensions, Guide Wire Introducers, Torque Devices, Hemostatic and Control Valves, and Guidewire Accessories.

on the basis of our examination of the quality assurance system under the requirements of Council Directive 93/42/EEC, Annex II excluding section 4. The quality assurance system meets the requirements of the directive. For the placing on the market of class III products an Annex II section 4 certificate is required.

For and on behalf of BSI, a Notified Body for the above Directive (Notified Body Number 2797):

Gary E Slack, Senior Vice President Medical Devices

First Issued: **2006-08-01** Date: **2021-02-05** Expiry Date: **2024-05-26**

...making excellence a habit.™

By Royal Charter

EC Certificate - Full Quality Assurance System

Supplementary Information to CE 510108

Issued To:

Abbott Vascular
3200 Lakeside Drive
Santa Clara
California
95054
USA

Number	Device Name	Intended purpose per IFU
Class III		
---	HI-TORQUE Guide Wires – Including AllStar, Extra S'port, Balance, Balance Middleweight, Intermediate, Standard, Extra S'port, Floppy II, Floppy II Extra Support, Traverse, Iron Man, and Wiggle	See CE 01497
---	HI-TORQUE Guide Wires with Hydrocoat Hydrophilic Coating and HI-TORQUE Guide Wires with Hydrophilic Coating – Including Cross-IT XT, Flexi Wire, Floppy II, Floppy II Extra Support, Standard, Intermediate, Traverse, Balance, Balance Middleweight, Whisper, Balance Heavyweight, and Balance Middleweight Universal	See CE 01753
---	Multi-Link RX Ultra Coronary Stent System	See CE 01834
---	Multi-Link Vision RX and Multi-Link Mini-Vision RX Coronary Stent System	See CE 71619
---	HI-TORQUE Pilot Guide Wire with Hydrophilic Coating	See CE 73066

First Issued: **2006-08-01** Date: **2021-02-05** Expiry Date: **2024-05-26**

By Royal Charter

EC Certificate - Full Quality Assurance System

Supplementary Information to CE 510108

Issued To:

Abbott Vascular
3200 Lakeside Drive
Santa Clara
California
95054
USA

Number	Device Name	Intended purpose per IFU
Class III		
---	X.ACT Carotid Stent System	See CE 503252
---	Emboshield NAV 6 Embolic Protection System and BareWire Filter Delivery Wires	See CE 504490
---	RX Accunet Embolic Protection System	See CE 518026
---	RX Acculink Carotid Stent System	See CE 518027
---	HI-TORQUE Guide Wires – Including SpartaCore, SteelCore 18, SteelCore 18 LT, and SupraCore	See CE 518028
---	HI-TORQUE Balance Middleweight Universal II Guide Wire	See CE 534263
---	HI-TORQUE Advance & HT Advance Lite Guide Wire	See CE 546723
---	HI-TORQUE Progress Guide Wire	See CE 553292
---	Trek and Mini Trek RX, TREK OTW and Mini TREK II OTW Coronary Dilatation Catheters	See CE 561260
---	HI-TORQUE Winn Guide Wire	See CE 564179
---	NC TREK RX Coronary Dilatation Catheter	See CE 565938

First Issued: **2006-08-01** Date: **2021-02-05** Expiry Date: **2024-05-26**

By Royal Charter

EC Certificate - Full Quality Assurance System

Supplementary Information to CE 510108

Issued To:

Abbott Vascular
3200 Lakeside Drive
Santa Clara
California
95054
USA

Number	Device Name	Intended purpose per IFU
Class III		
---	HI-TORQUE Balance Middleweight Elite Guide Wire	See CE 568482
---	HI-TORQUE Powerturn Guide Wires	See CE 581813
---	NC TREK OTW Coronary Dilatation Catheter	See CE 584431
---	HI-TORQUE JET Guide Wires	See CE 591655
---	Graftmaster RX Coronary Stent Graft System	See CE 592549
---	TRAVELER RX Coronary Dilatation Catheter	See CE 602426
---	NC TRAVELER Coronary Dilatation Catheter	See CE 609165
---	HI-TORQUE VersaTurn Guide Wire	See CE 615774
---	Everolimus Eluting Coronary Stent System XIENCE V	See CE 629247
---	Everolimus Eluting Coronary Stent System XIENCE PRIME SV, XIENCE PRIME, XIENCE PRIME LL	See CE 629248
---	Everolimus Eluting Peripheral Stent System XIENCE PRIME BTK	See CE 629249

First Issued: **2006-08-01** Date: **2021-02-05** Expiry Date: **2024-05-26**

...making excellence a habit.™

By Royal Charter

EC Certificate - Full Quality Assurance System

Supplementary Information to CE 510108

Issued To:

Abbott Vascular
3200 Lakeside Drive
Santa Clara
California
95054
USA

Number	Device Name	Intended purpose per IFU
Class III		
---	MULTI-LINK 8 Coronary Stent System	See CE 629250
---	XIENCE Xpedition Everolimus Eluting Coronary Stent System	See CE 632826
---	XIENCE Pro Everolimus Eluting Coronary and Peripheral Stent Systems	See CE 632827
---	XIENCE Alpine Everolimus Eluting Coronary Stent Systems	See CE 632828
---	MitraClip NT/NTR/XTR Delivery System and Steerable Guide Catheter	See CE 643983
---	HI-TORQUE TurnTrac Guide Wire	See CE 679931
---	XIENCE Sierra Everolimus Eluting Coronary Stent System	See CE 680375
---	TriClip Delivery System and Steerable Guide Catheter	See CE 712450

First Issued: **2006-08-01** Date: **2021-02-05** Expiry Date: **2024-05-26**

...making excellence a habit.™

EC Certificate - Full Quality Assurance System

Supplementary Information to CE 510108

Issued To:

Abbott Vascular
3200 Lakeside Drive
Santa Clara
California
95054
USA

Number	Device Name	Intended purpose per IFU
Class IIb		
47932	Stent Systems	Stent Systems are implants intended to improve luminal diameter of peripheral vasculature and biliary strictures.
52747	Vessel Closure Devices	Vessel Closure Devices are intended to percutaneously deliver sutures to close femoral vessel access sites.
63255	Vessel Closure Devices	Vessel Closure Devices are intended to percutaneously deliver clips to close femoral vessel access sites.
Class IIa		
MD 0106	Inflation Devices	N/A
MD 0106	Inflation Device Accessory Kits	N/A
MD 0106	Percutaneous Transluminal Angioplasty (PTA) Catheters	N/A
MD 0106	Guidewires	N/A

First Issued: **2006-08-01** Date: **2021-02-05** Expiry Date: **2024-05-26**

By Royal Charter

EC Certificate - Full Quality Assurance System

Supplementary Information to CE 510108

Issued To:

Abbott Vascular
3200 Lakeside Drive
Santa Clara
California
95054
USA

Number	Device Name	Intended purpose per IFU
Class Is		
MDS 7006	Torque Device	N/A
MDS 7006	COPILOT Bleedback Control Valve	N/A
MDS 7006	DOC Guide Wire Extension	N/A
MDS 7006	Rotating Hemostatic Valve .096 and .115	N/A
MDS 7006	Guide Wire Introducer	N/A
MDS 7006	Guide Wire Accessory kit	N/A
MDS 7006	Guide Wire Accessory kit with COPILOT Bleedback Control Valve	N/A
MDS 7006	LOC .035 Guide Wire Extension	N/A

First Issued: **2006-08-01** Date: **2021-02-05** Expiry Date: **2024-05-26**

...making excellence a habit.™

By Royal Charter

EC Certificate - Full Quality Assurance System

Directive 93/42/EEC on Medical Devices, Annex II excluding Section 4

List of Significant Subcontractors

Recognised as being involved in services relating to the product covered by:

Certificate No: **CE 510108**

Date: **2021-02-05**

Issued To: **Abbott Vascular**
3200 Lakeside Drive
Santa Clara
California
95054
USA

Subcontractor:	Service(s) supplied
Abbott Vascular 26531 Ynez Road Temecula California 92591 USA	**Design** **Development** **Manufacture** **Radiation (E Beam Sterilization)**
Abbott Vascular 3885 Bohannon Drive Menlo Park CA 94025 USA	**Design** **Development** **Manufacture**
Abbott Vascular 52 Calle, 3, B31, Coyol Free Zone El Coyol Alajuela Costa Rica	**Manufacture**
Abbott Vascular Building PR-17, Road #2 km. 58.0 Cruce Davila Barceloneta 00617 Puerto Rico	**Manufacture**

...making excellence a habit.™

By Royal Charter

EC Certificate - Full Quality Assurance System

Directive 93/42/EEC on Medical Devices, Annex II excluding Section 4

List of Significant Subcontractors

Recognised as being involved in services relating to the product covered by:

Certificate No: **CE 510108**

Date: **2021-02-05**

Issued To: **Abbott Vascular**
3200 Lakeside Drive
Santa Clara
California
95054
USA

Subcontractor:	**Service(s) supplied**
Abbott Vascular Cashel Road Clonmel Tipperary Ireland	**Design** **Development** **Manufacture**
Abbott Vascular International BVBA Park Lane Culliganlaan, 2B 1831 Diegem Belgium	**EU Representative**
Abbott Vascular Netherlands B.V. Argonstraat 1 6422 PH Heerlen The Netherlands	**Labelling** **Packaging**
Abbott West Distribution Center 42301 Zevo Drive Temecula CA 92590 USA	**Manufacture**

...making excellence a habit.™

By Royal Charter

EC Certificate - Full Quality Assurance System

Directive 93/42/EEC on Medical Devices, Annex II excluding Section 4

List of Significant Subcontractors

Recognised as being involved in services relating to the product covered by:

Certificate No: **CE 510108**

Date: **2021-02-05**

Issued To: **Abbott Vascular**
3200 Lakeside Drive
Santa Clara
California
95054
USA

Subcontractor:	**Service(s) supplied**
ADMEDES GmbH Rastatter Str. 15 75179 Pforzheim Germany	**Manufacture**
Availmed S.A. de C.V. C. Industrial Lt. 001 Mz.105 No. 20905 Int. A Col. Cd. Industrial Tijuana Baja California 22444 Mexico	**Manufacture**
Novartis Pharma AG Lichstrasse 35 Basel CH-4056 Switzerland	**Crucial Supplier**

...making excellence a habit.™

By Royal Charter

EC Certificate - Full Quality Assurance System

Directive 93/42/EEC on Medical Devices, Annex II excluding Section 4

List of Significant Subcontractors

Recognised as being involved in services relating to the product covered by:

Certificate No: **CE 510108**

Date: **2021-02-05**

Issued To: **Abbott Vascular**
3200 Lakeside Drive
Santa Clara
California
95054
USA

Subcontractor:	**Service(s) supplied**
Parter Sterilization Services LLC 17115 Kingsview Ave Carson CA 90746 USA	**ETO Sterilization**
Sterigenics Costa Rica S.R.L. Zona Franca PROPARK Calle Principal, Edificio 10 El Coyol Alajuela Costa Rica	**ETO Sterilization**
Sterigenics Germany GmbH Kasteler Strasse 45 Wiesbaden 65203 Germany	**ETO Sterilization**

...making excellence a habit.™

By Royal Charter

EC Certificate - Full Quality Assurance System

Directive 93/42/EEC on Medical Devices, Annex II excluding Section 4

List of Significant Subcontractors

Recognised as being involved in services relating to the product covered by:

Certificate No: **CE 510108**

Date: **2021-02-05**

Issued To: **Abbott Vascular**
3200 Lakeside Drive
Santa Clara
California
95054
USA

Subcontractor:	**Service(s) supplied**
Sterigenics Radiation Technologies, LLC 7695 Formula Place San Diego California 92121 USA	**Radiation (E Beam Sterilization)**
Sterigenics UK Limited Cotes Park Estate Somercotes Alfreton DE55 4NJ United Kingdom	**ETO Sterilization**
Sterigenics US, LLC 4900 Gifford Avenue Los Angeles California 90058 USA	**ETO Sterilization**

...making excellence a habit.™

By Royal Charter

EC Certificate - Full Quality Assurance System

Directive 93/42/EEC on Medical Devices, Annex II excluding Section 4

List of Significant Subcontractors

Recognised as being involved in services relating to the product covered by:

Certificate No: **CE 510108**

Date: **2021-02-05**

Issued To: **Abbott Vascular**
3200 Lakeside Drive
Santa Clara
California
95054
USA

Subcontractor:	**Service(s) supplied**
Synergy Health AST, SRL B16, Street 4, Avenue 0 20102 El Coyol Alajuela Costa Rica	**Radiation (E Beam Sterilization)**
Synergy Health Ireland Ltd. IDA Business & Technology Park Sragh Industrial Estate Tullamore, Co. Offaly Ireland	**ETO Sterilization** **Radiation (E Beam Sterilization)**

...making excellence a habit.™

By Royal Charter

EC Certificate - Full Quality Assurance System

Certificate History

Certificate No: **CE 510108**

Date: **2021-02-05**

Issued To: **Abbott Vascular**
3200 Lakeside Drive
Santa Clara
California
95054
USA

Date	Reference Number	Action
01 August 2006	4068482	First Issue based on CE 00946.
13 March 2007	4941821	Isotron Ireland, Ltd added to the list of significant subcontractors.
15 November 2007	7104034	Addition of Abbott Ireland (Galway) to the list of significant subcontractors. Addition of design and development of services supplied by Temecula.
01 August 2008	7200338	Addition of Abbott Vascular, Murrieta and Abbott Vascular, Barceloneta to list of significant subcontractors for manufacturing activities. Removal of Abbott Vascular, Dorado facility.
18 February 2009	7292729	Transfer of product families from Abbott Vascular, Vascular Solutions FQA certificate CE 525963. Remove Business Unit name (Cardiac Therapies) from the 'issued to' address and the Abbott Vascular, Murrieta facility address in the list of subcontractors. Addition of AD)MEDES Schuessler GmbH to list of significant subcontractors for manufacturing activities.
20 April 2010	7510769	Addition of Creganna-Tactx Medical to list of significant subcontractors for manufacturing activities and addition of Abbott Vascular International BVBA as EU Authorized Representative.

By Royal Charter

EC Certificate - Full Quality Assurance System
Certificate History

Certificate No: **CE 510108**
Date: **2021-02-05**
Issued To: **Abbott Vascular**
3200 Lakeside Drive
Santa Clara
California
95054
USA

Date	Reference Number	Action
12 October 2010	7581791	Renewal of certification Removal of Sterigenics (Salt Lake City), Abbott Ireland (Galway) and Isotron Ireland as significant subcontractors. Remove Abbott Vascular Sterilization from Clonmel manufacturing site. Addition of Sterigenics (New Mexico) as significant subcontractor. Removal of atherctomy catheters and motor drive units from the scope. Redefine stents as stent systems. Addition of Abbott West Distribution Center and Abbott Vascular Devices Holland B.V. as a significant subcontractor.
10 November 2011	7765633	Addition of LEONI Studer Hard AG to list of significant subcontractors for E beam sterilization.
13 December 2011	7766500	Addition of the Abbott Vascular Manufacturing Site in Alajuela, Costa Rica as a significant subcontractor.
31 May 2012	7804693	Addition of Synergy Health Ireland Ltd as a significant subcontractor for e-beam sterilization. Name of subcontractor Abbott Vascular Devices Holland B.V. changed to Abbott Vascular Netherlands B.V. and address updated. Administrative changes on certificate.
19 September 2012	7903213	Addition of Accellent as significant subcontractor for TREK family. Addition of Abbott Vascular Costa Rica Main Building as significant subcontractor for manufacturing.

By Royal Charter

EC Certificate - Full Quality Assurance System
Certificate History

Certificate No: **CE 510108**
Date: **2021-02-05**
Issued To: **Abbott Vascular**
3200 Lakeside Drive
Santa Clara
California
95054
USA

Date	Reference Number	Action
21 December 2012	7911227	Addition of Abbott (Nutritional) Ireland Sligo to the list of significant subcontractors for the sterilization. Scope updated to include "including covered stents".
02 July 2013	7991114	Removal of Abbott Vascular - Alajuela Costa Rica, as a significant subcontactor. Change name of subcontractor from LEONI Studer Hard AG to LEONI Studer AG. Reclassify Funnel Introducer, Guide Wire Introducer, Duostat Rotating Hemostatic Valve, Rotating Hemostatic Valve, Guide Wire Introducer Accessory Kit and Guide Wire Accessory Kit with CoPilot from Class IIa to Class I (Sterile).
May 28, 2014	8164752	Addition of NovoSci and Sterigenics in Wiesbaden for the service of ETO sterilization, Synergy Health in Costa Rica for the service of E-beam sterilization and Availmed S.A. de C.V. for service of manufacturer due to several product transfers.
05 February 2015	8268209	Update to add Drug Eluting Stents to the scope. Addition of significant subcontractors OK International, LTD and Sterigenics UK Limited.
31 March 2015	8283470	Addition of Vessel Closure Devices to the scope of certification as part of a transfer from the Abbott Vascular Redwood City facility. Addition of significant subcontractors Teleflex Medical and Acme Monoco for manufacture and Synergy Health Ireland Ltd for EO Sterilization.

bsi.

By Royal Charter

EC Certificate - Full Quality Assurance System
Certificate History

Certificate No: **CE 510108**
Date: **2021-02-05**
Issued To: **Abbott Vascular**
3200 Lakeside Drive
Santa Clara
California
95054
USA

Date	Reference Number	Action
13 April 2015	8296689	Addition of Bioresorbable Vascular Scaffold (BVS) Systems to the scope of certification.
08 July 2015	8359594	Addition of Sterigenics Costa Rica S.R.L. as a significant subcontractor for ETO sterilization.
07 September 2015	8411826	Renewal of certification. Removal of subcontractors: Accellent, Inc., Creganna, NovoSci Corp and OK International, LTD. Removal of Abbott Vascular Murrieta site: facility closed down. Typo correction (LEONI Studer AG address, Sterigenics names).
19 December 2015	8427566	Scope extension to include the MitraClip NT System under Abbott Vascular's Quality System.
13 July 2016	8558860	Removal of "coronary and peripheral guiding catheters" from scope of certification and the addition of Availmed S.A. de C.V. Baja California location as significant subcontractor.
22 December 2017	8863184	Scope change from "Arterial" to "Femoral" for vessel closure devices. Removal of Availmed in La Mesa, Tijuana, Mexico for manufacturing services, and LEONI in Switzerland for Ebeam Sterilization. Addition of NOVARTIS as a crucial supplier. Add design and development services to Abbott in Clonmel, Ireland.
27 February 2019	7780598	Traceable to NB 0086.

bsi.

By Royal Charter

EC Certificate - Full Quality Assurance System
Certificate History

Certificate No: **CE 510108**
Date: **2021-02-05**
Issued To: **Abbott Vascular**
3200 Lakeside Drive
Santa Clara
California
95054
USA

Date	Reference Number	Action
12 February 2020	3042205	Remove "Bioresorbable Vascular Scaffold (BVS) Systems" from the scope. Remove subcontractors "Abbott Ireland" Ballytivnan location and "Sterigenics US, LLC" New Mexico location. Update address for Sterigenics US, LLC in Los Angeles.

...making excellence a habit.™

By Royal Charter

EC Certificate - Full Quality Assurance System
Certificate History

Certificate No: **CE 510108**
Date: **2021-02-05**
Issued To: **Abbott Vascular**
3200 Lakeside Drive
Santa Clara
California
95054
USA

Date	Reference Number	Action
02 June 2020	9718057	Certificate Renewal. Scope rewrite for clarity. Clearly denoting what devices are sterile in scope, changing "dilation" to "dilatation", listing inflation devices and inflation accessories (Class IIa) in the first paragraph, noting that "systems" applies to all stent types, noting specific device categories as Class Is in the second paragraph, noting femoral vessel closure devices are systems, and corrected capitalization of proper names throughout. Scope change to add the word "tricuspid" to "mitral valve repair systems" to cover new device TriClip NT/XT CE 712450. Added Product Table. Removed Subcontractors: Nitinol Devices and Components, Fremont, CA and Costa Rica locations, Rose Technologies, Grand Rapids, MI, Acme Monaco, New Britain, CT and Teleflex, Jaffrey, NH. Update Subcontractor Name and Addresses to match ISO certificate – ADMEDES GmbH, Rastatter Str. 15, 75179 Pforzheim, Germany and Synergy Health AST, SRL, B16 Street 4, Avenue 0, 20102 El Coyol Alajuela, Costa Rica. Remove "Distribution" service supplied for subcontractors Abbott Vascular (Menlo Park), Abbott Vascular Netherlands B.V., and Abbott West Distribution Center.

By Royal Charter

EC Certificate - Full Quality Assurance System
Certificate History

Certificate No: **CE 510108**

Date: **2021-02-05**

Issued To: **Abbott Vascular**
3200 Lakeside Drive
Santa Clara
California
95054
USA

Date	Reference Number	Action
Current	3369562	Administrative update to product table: • clarification to the intended purpose statement for Class IIb Stent Systems • separation between suture and clip for the Vessel Closure devices. Addition of the GMDN 63255 Update the name of the critical subcontractor Sterigenics US, LLC (San Diego - California) with the name Sterigenics Radiation Technologies, LLC (San Diego - California).

Xience Pro™ S

EVEROLIMUS ELUTING CORONARY STENT SYSTEM

XIENCE™ STENT: MOST STUDIED, MOST IMPLANTED STENT IN THE WORLD

15 MILLION+ Implants[1]

120+ Clinical Trials[1]

DAPT Studied in **20,000+** Patients[2]

125,000+ Patients Studied[1]

10+ Years of Data

STOPDAPT2 Study **0.1%** Definite stent thrombosis at 1 year after 1 month of DAPT[3]

1. 15,000,000 implants number is based on data of DES implants through Q1 2020. Data on file at Abbott.
2. Généreux P, et al. *Circ Cardiovasc Interv.* 2015;8(5):1-16; Natsuaki et al., *Cardiovasc Interv and Ther.* 2016. 31:196–209; Watanabe H, et al. *JAMA.* 2019;321(24):2414-2427; Hahn J, et al. ACC 2019 – SMART CHOICE; Valgimigli M, et al. *Circulation.* 2012;125:2015-2026; Gilard M, et al. *J Am Coll Cardiol* 2015;65:777-786; Hong SJ, et al. *J Am Coll Cardiol Intv.* 2016;9:1438–1446. Gwon HC, et al. ACC 2011 - EXCELLENT.
3. Watanabe H, et al. *JAMA.* 2019;321(24):2414-2427 - STOPDAPT 2.

ORDERING INFORMATION

STENT DIAMETER	LENGTH								POST-DILATATION LIMIT
	8 mm	12 mm	15 mm	18 mm	23 mm	28 mm	33 mm	38 mm	
2.0 mm	1508200-08	1508200-12	1508200-15	1508200-18	1508200-23	1508200-28	1508200-33	1508200-38	3.75 mm
2.25 mm	1508225-08	1508225-12	1508225-15	1508225-18	1508225-23	1508225-28	1508225-33	1508225-38	3.75 mm
2.5 mm	1508250-08	1508250-12	1508250-15	1508250-18	1508250-23	1508250-28	1508250-33	1508250-38	3.75 mm
2.75 mm	1508275-08	1508275-12	1508275-15	1508275-18	1508275-23	1508275-28	1508275-33	1508275-38	3.75 mm
3.0 mm	1508300-08	1508300-12	1508300-15	1508300-18	1508300-23	1508300-28	1508300-33	1508300-38	3.75 mm
3.25 mm	1508325-08	1508325-12	1508325-15	1508325-18	1508325-23	1508325-28	1508325-33	1508325-38	3.75 mm
3.5 mm	1508350-08	1508350-12	1508350-15	1508350-18	1508350-23	1508350-28	1508350-33	1508350-38	5.5 mm
4.0 mm	1508400-08	1508400-12	1508400-15	1508400-18	1508400-23	1508400-28	1508400-33	1508400-38	5.5 mm

STENT SPECIFICATIONS	
Stent Design	**MULTI-LINK, 3-3-3, Peak-to-Valley Design**
Stent Material	**L-605 Cobalt Chromium**
Drug	**Everolimus**
Drug Dose	**1 µg/mm²**
Polymer	**Fluorinated Copolymer**
Strut Thickness	**0.0032″ (81 µm)**
MRI Compatibility	**MR Conditional (see IFU for specific conditions)**
Shortening	**0% (maximum expansion)[1]**
Post-Dilatation Limit	**Sizes** 2.25-3.25 mm 3.5-4.0 mm / **Post-Dil Limit** 3.75 mm 5.5 mm

DELIVERY SYSTEM SPECIFICATIONS		
Nominal Pressure	**9 atm for 2.25-2.5 mm; 12 atm for 2.75-4.0 mm**	
Rated Burst Pressure	**16 atm for All Diameters**	
Shaft Measurements	**Proximal** 2.1F/0.71 mm	**Distal** 2.7F/0.89 mm
Min. GC/Sheath Diameter	**5F/0.056″/1.42 mm**	
Balloon Material	**Pebax® 72D**	
Crossing Profile	**0.039″ (3.0 x 18 mm)**	
Tip Entry Profile	**0.017″ (3.0 x 18 mm)**	
Working Catheter Length	**145 cm**	

1. Test(s) performed by and data on file at Abbott

CAUTION: This product is intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at *www.vascular.eifu.abbott* or at *medical.abbott/manuals* for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Information contained herein for DISTRIBUTION outside the U.S. only. Check the regulatory status of the device in areas where CE marking is not the regulation in force.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.

Abbott International BVBA
Park Lane, Culliganlaan 2B, 1831 Diegem, Belgium, Tel: 32.2.714.14.11

www.cardiovascular.abbott

Abbott





Xience Pro™ S

EVEROLIMUS ELUTING CORONARY STENT SYSTEM

Redefining deliverability in complex lesions

Information contained herein for DISTRIBUTION outside of the U.S. only. Check the regulatory status of the device in areas where CE marking is not the regulation in force.

Abbott

Redefining deliverability in complex lesions

Xience Pro™ S
EVEROLIMUS ELUTING CORONARY STENT SYSTEM

XIENCE PRO™ S STENT DESIGN



→ PRECISE

- 100% accurate marker placement[1]
- Zero shortening for precise stent placement[2]

→ STRONG

- Great longitudinal strength[1]
- Outstanding stent retention[1]
- Robust radial strength[1]

→ SLIM

- Ultra low crossing profile[3]

SLIM FLEX TECHNOLOGY

Includes tight crests and smooth links that allow tighter crimping for low crossing profile[1]

ELONGATED BAR ARMS

Deliver up to 5.5 mm maximum expansion in 3.5 mm and 4.0 mm diameter sizes[1]

STENT DELIVERY SYSTEM FOR COMPLEX CASES

Design innovations built to provide the flexibility, crossability, and pushability needed for even the most complex cases



→ MAXIMAL EXPANSION[1]

Up to **5.5 mm** in large sizes

1. Test(s) performed by and data on file at Abbott.

ULTRA LOW CROSSING PROFILE[3]

XIENCE Pro™ A	Resolute Onyx‡	Synergy‡	XIENCE Pro™ S
0.0425″	0.0405″	0.0393″	0.0390″

1. Data on file at Abbott.
2. Test(s) performed by and data on file at Abbott. Refers to 4.0 mm diameter size expanded to 5.5 mm.
3. Test(s) performed by and data on file at Abbott. 3.0 mm diameter size tested, compared to XIENCE Pro A, Synergy, Resolute Onyx.

SPECIFICALLY DESIGNED FOR THE TREATMENT OF EVEN COMPLEX PATIENTS

LARGE VESSELS

- Post-dilatation up to 5.5 mm[1]
- Superior coating[2] integrity, even at max expansion[3]
- Zero shortening[3]

SIDE BRANCH ACCESS

- Largest side branch access in workhorse sizes[2]
- Stent design maintains integrity even when cell is opened[4]

RADIAL ACCESS

- Unsurpassed pushability: Requires less force to cross lesion[4]
- 5 French compatible
- Ultra low crossing profile[4]

CTO

- True Center Tip designed succeed in CTOs
- Ultra low crossing profile[4]
- The only CTO-indicated stent
- Unrivaled safety in CTOs[5]

DIABETES

- Long lengths for small vessels
- Less force needed to cross tight lesions[4]
- Proven safety and efficacy in diabetic patients[6]

1. Test(s) performed by and data on file at Abbott. 5.5 mm maximum expansion in 3.5 and 4.0 diameter sizes.
2. Test(s) performed by and data on file at Abbott.
3. Test(s) performed by and data on file at Abbott. Refers to 4.0 mm diameter size expanded to 5.5 mm.
4. Test(s) performed by and data on file at Abbott. 3.0 mm diameter size tested, compared to XIENCE Pro A, Synergy, Resolute Onyx.
5. EXPERT CTO Trial data demonstrated 1% definite stent thrombosis and 6.3% TLR at 1 year. Kandzari D, et al. "Safety and Effectiveness of Everolimus-Eluting Stents in Chronic Total Coronary Occlusion Revascularization." *JACC* 2015.
6. TUXEDO 2-Year Data, Upendra Kaul, TCT 2016.



Xience Pro™ S

EVEROLIMUS ELUTING CORONARY STENT SYSTEM

Redefining deliverability in complex lesions

COMPLIANCE CHART

PRESSURE		STENT ID BY SYSTEM DIAMETER							
atm	kPa	2.0 mm	2.25 mm	2.5 mm	2.75 mm	3.0 mm	3.25 mm	3.5 mm	4.0 mm
8	811	2.05	2.27	2.53	2.6	2.79	2.98	3.36	3.74
9	912	2.09	2.31	2.58	2.66	2.86	3.05	3.42	3.82
10	1,013	2.13	2.35	2.63	2.71	2.91	3.11	3.47	3.89
11	1,115	2.16	2.39	2.67	2.75	2.96	3.17	3.52	3.95
12	1,216	2.19	2.42	2.71	2.79	3.0	3.22	3.56	4.01
13	1,317	2.22	2.45	2.74	2.82	3.04	3.26	3.59	4.05
14	1,419	2.24	2.48	2.77	2.86	3.07	3.3	3.63	4.1
15	1,520	2.27	2.51	2.8	2.88	3.1	3.33	3.66	4.14
16	1,621	2.29	2.53	2.83	2.91	3.13	3.37	3.7	4.18
17	1,723	2.31	2.56	2.85	2.94	3.16	3.4	3.73	4.22
18	1,824	2.33	2.58	2.88	2.97	3.19	3.43	3.77	4.26
19	1,925	2.35	2.6	2.91	3.0	3.21	3.46	3.81	4.29
20	2,027	2.38	2.63	2.94	3.03	3.24	3.5	3.84	4.34

Nominal **RBP**

CAUTION: This product is intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at *www.vascular.eifu.abbott* or at *medical.abbott/manuals* for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Information contained herein for DISTRIBUTION outside the U.S. only. Check the regulatory status of the device in areas where CE marking is not the regulation in force.

Tests performed by and data on file at Abbott. Photos on file at Abbott.

Abbott International BVBA
Park Lane, Culliganlaan 2B, 1831 Diegem, Belgium, Tel: 32.2.714.14.11

www.cardiovascular.abbott

Abbott